2 reports of this reaction
2.3% of all PULSATILLA VULGARIS reports
#10 most reported adverse reaction
HAEMATOMA is the #10 most commonly reported adverse reaction for PULSATILLA VULGARIS. There are 2 FDA adverse event reports linking PULSATILLA VULGARIS to HAEMATOMA. This represents approximately 2.3% of all 86 adverse event reports for this drug.
Patients taking PULSATILLA VULGARIS who experience haematoma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMATOMA is a less commonly reported adverse event for PULSATILLA VULGARIS, but still significant enough to appear in the safety profile.
In addition to haematoma, the following adverse reactions have been reported for PULSATILLA VULGARIS:
The following drugs have also been linked to haematoma in FDA adverse event reports:
HAEMATOMA has been reported as an adverse event in 2 FDA reports for PULSATILLA VULGARIS. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMATOMA accounts for approximately 2.3% of all adverse event reports for PULSATILLA VULGARIS, making it a notable side effect.
If you experience haematoma while taking PULSATILLA VULGARIS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.